PATIENT-REPORTED EXPERIENCES WITH SELF-INJECTIONS USING PREFILLED SYRINGE AND AUTOINJECTOR DEVICES IN AN OPEN-LABEL, LONG-TERM STUDY OF GALCANEZUMAB IN PATIENTS WITH MIGRAINE

被引：0
|
作者：
Stauffer, V. L. [1 ]
Sides, R. [1 ]
Lanteri-Minet, M. [2 ]
Kielbasa, W. [1 ]
Jin, Y. [1 ]
Selzler, K. J. [1 ]
Tepper, S. J. [3 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Ctr Hosp Univ Nice, Nice, France
[3] Geisel Sch Med Dartmouth, Hanover, NH USA
来源：
CEPHALALGIA | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS2018-1
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [1] Patient-reported Experiences with Self-injections Using Prefilled Syringe and Autoinjector Devices in an Open-label, Long-term Study of Galcanezumab in Patients with Migraine
    Stauffer, V
    Sides, R.
    Kielbasa, W.
    Jin, Y.
    HEADACHE, 2018, 58 : 179 - 179
  • [2] Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies
    Stauffer, Virginia L.
    Sides, Ryan
    Lanteri-Minet, Michel
    Kielbasa, William
    Jin, Yan
    Selzler, Katherine J.
    Tepper, Stewart J.
    PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1785 - 1795
  • [3] A Phase 3, Long-Term, Open-Label Safety Study of Self-Administered Galcanezumab Injections in Patients with Migraine
    Stauffer, Virginia L.
    Sides, Ryan
    Camporeale, Angelo
    Skljarevski, Vladimir
    Ahl, Jonna
    Aurora, Sheena K.
    CEPHALALGIA, 2017, 37 : 330 - 331
  • [4] A long-term open-label safety study of galcanezumab in Japanese patients with migraine
    Hirata, Koichi
    Takeshima, Takao
    Sakai, Fumihiko
    Tatsuoka, Yoshihisa
    Suzuki, Norihiro
    Igarashi, Hisaka
    Nakamura, Tomomi
    Ozeki, Akichika
    Yamazaki, Hiroyoshi
    Skljarevski, Vladimir
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 721 - 733
  • [5] Patient Functioning and Disability among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
    McAllister, Peter
    Ford, Janet H.
    Stauffer, Virginia L.
    Sexson, Matthew
    Ayer, David
    Wang, Shufang
    NEUROLOGY, 2020, 94 (15)
  • [6] Patient Functioning and Disability Among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
    McAllister, P.
    Ford, J.
    Stauffer, V
    Sexson, M.
    Ayer, D.
    Wang, S.
    HEADACHE, 2019, 59 : 99 - 100
  • [7] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Angelo Camporeale
    David Kudrow
    Ryan Sides
    Shufang Wang
    Annelies Van Dycke
    Katherine J. Selzler
    Virginia L. Stauffer
    BMC Neurology, 18
  • [8] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Camporeale, Angelo
    Kudrow, David
    Sides, Ryan
    Wang, Shufang
    Van Dycke, Annelies
    Selzler, Katherine J.
    Stauffer, Virginia L.
    BMC NEUROLOGY, 2018, 18
  • [9] Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
    Ford, Janet H.
    Stauffer, Virginia L.
    McAllister, Peter
    Akkala, Sreelatha
    Sexson, Matthew
    Ayer, David W.
    Wang, Shufang
    QUALITY OF LIFE RESEARCH, 2021, 30 (02) : 455 - 464
  • [10] Correction to: Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
    Janet H. Ford
    Virginia L. Stauffer
    Peter McAllister
    Sreelatha Akkala
    Matthew Sexson
    David W. Ayer
    Shufang Wang
    Quality of Life Research, 2021, 30 : 465 - 466
12345